Furthermore, retrospective studies with IFN-α2a, IFN-α2b or IFN-β1a in combination with ribavirin have not shown a clear benefit in patients with MERS [6–8, 12]. This evidence concerns the gene IFNA2 and Middle East respiratory syndrome.